Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post Marketing Surveillance, Multicenter, Open-Label, Dose-Titrating, 4-Week Study Evaluating The Efficacy, Tolerability And Safety Of Olmesartan Medoxomil 20mg In Combination With 12.5mg Hydrochlorothiazide In Subjects With Stage 1 To Stage 2 Hypertension

NCT00796159 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00796159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00796159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post Marketing Surveillance, Multicenter, Open-Label, Dose-Titrating, 4-Week Study Evaluating The Efficacy, Tolerability And Safety Of Olmesartan Medoxomil 20mg In Combination With 12.5mg Hydrochlorothiazide In Subjects With Stage 1 To Stage 2 Hypertension
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
July 31, 2007
Completion date
December 31, 2008
Enrollment
1,723 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension